Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Adverum Biotechnologies Inc.

An announcement from Adverum Biotechnologies ( ($ADVM) ) is now available. On November 20, 2025, Adverum Biotechnologies received a termination not...

Adverum Biotechnologies Faces Lease Termination Notice

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Adverum Biotechnologies today and set a price target of $5.50. The company’s...

Mizuho Securities Remains a Buy on Adverum Biotechnologies (ADVM)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cabaletta Bio (CABA – Research Report), Actinium P...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cabaletta Bio (CABA), Actinium Pharmaceuticals (ATNM) and Adverum Biotechnologies (ADVM)

RBC Capital analyst Lisa Walter maintained a Hold rating on Adverum Biotechnologies yesterday and set a price target of $4.00. The company’s shares...

RBC Capital Keeps Their Hold Rating on Adverum Biotechnologies (ADVM)

Adverum Biotechnologies (($ADVM)) announced an update on their ongoing clinical study. Adverum Biotechnologies is conducting a Phase 3 clinical stu...

Adverum Biotechnologies’ Phase 3 Study on Ixo-vec: A Potential Game-Changer for AMD Treatment

Eli Lilly ($LLY) is strengthening its presence in genetic medicine with a deal worth $261.7 million to acquire Adverum Biotechnologies ($ADVM), a c...

M&A News: Eli Lilly’s (LLY) $262M Acquisition of Adverum Bolsters Gene Therapy Push

Adverum Biotechnologies ( ($ADVM) ) has shared an update. On October 24, 2025, Adverum Biotechnologies entered into a merger agreement with Eli Lil...

Current Quarter	$-0.58	Next Quarter	$-0.35
Current Year	$-5.11	Next Year	$-2.24
QoQ Growth	+39.7%	YoY Growth	+56.2%
3Y EPS CAGR	-64.8%	Target Price	$9.90
Consensus	Buy	Upside	+138.3%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ADVM	$4.16	-0.84%	172.13K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ADVM	$4.16	-0.8%	172.13K
3
4
5
6

ADVM

ADVM

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Adverum Biotechnologies Inc. Data in Excel

Get Adverum Biotechnologies Inc. Data in Excel